Market revenue in 2023 | USD 632.1 million |
Market revenue in 2030 | USD 883.7 million |
Growth rate | 4.9% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase IV |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Icon PLC, Syneos Health, Medpace Holdings Inc, PPD, Labcorp Drug Development, Pfizer Inc, IQVIA Holdings Inc, Premier Research, QPS Holdings, Emmes |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pediatric clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 32.21% in 2023. Horizon Databook has segmented the France pediatric clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the France pediatric clinical trials market, including forecasts for subscribers. This country databook contains high-level insights into France pediatric clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account